BioSpace News Archive

Despite concerns regarding neffy’s lack of clinical evidence, the panel of experts voted in favor of the nasal spray’s approval for the emergency treatment of type 1 allergic reactions.

Nirsevimab lowered hospitalizations due to RSV-related lower respiratory tract disease by 83.21%. Friday’s data drop comes ahead of next week’s advisory committee meeting for Pfizer’s RSV hopeful.

Lawmakers on Thursday voted 18–3 to increase oversight of pharmacy benefit managers and limit their practice of spread pricing, when PBMs charge payers for drugs more than they pay pharmacies.

Preliminary trial results show the GSK five-in-one meningitis vaccine is immunologically effective against the most common strains, as the FDA decision date for Pfizer’s candidate looms.

Veracyte, Inc. announced that new data show the use of the Prosigna Breast Cancer Assay altered treatment decisions for patients with early-stage breast cancer, including significantly reducing the use of chemotherapy among those with clinically high-risk disease.

Sol-Gel Technologies, Ltd., a dermatology company with two innovative dermatology products, EPSOLAY and TWYNEO, that were launched in the U.S., SGT-610, which is Phase 3-ready, and an earlier-stage SGT-210, announced financial results for the first quarter ended March 31, 2023 and provided a corporate update.

Plus Therapeutics, Inc., a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, announced that Norman LaFrance, M.D., Chief Medical Officer and Senior Vice President, will participate in the “Know All Your Treatment Options 2023” virtual educational event organized by EndBrainCancer Initiative.

Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that Peter Mariani, Executive Vice President & Chief Financial Officer, will participate in a fireside chat at the JMP Securities Life Sciences Conference in New York on Monday, May 15, 2023 at 3:00 p.m. ET.

Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra” or the “Company”), a clinical-stage biotechnology company developing innovative therapies for the localized treatment of chronic rhinosinusitis (CRS), today reported its financial results for the first quarter ended March 31, 2023 and provided a corporate update.

Aktis Oncology announced Matthew Roden, PhD, President and Chief Executive Officer, and Shulamit Ron-Bigger, PhD, Chief Operating Officer, will participate in the 2023 Guggenheim Healthcare Talks: Radiopharmaceuticals Day, held on May 15 in New York City.